Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
- Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care
- Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia a new treatment option